Nautilus Biotechnology Business Summary

Nautilus Biotechnology, Inc. (NAUT) is a development-stage life sciences company that operates on a platform-as-a-service and product-sales business model, primarily targeting the high-growth proteomics market. The company aims to generate revenue through the commercialization of its Voyager™ Platform, a benchtop system designed for single-molecule protein analysis, supplemented by recurring sales of proprietary reagent kits and software-based data analysis subscriptions. Currently in its pre-revenue phase, Nautilus launched a fee-for-service Early Access Program in January 2026, focusing on tau proteoform assays for neurodegenerative research, with a full commercial rollout of instruments and consumables slated for late 2026. The company competes directly with established and emerging proteomics players such as Seer (SEER), Quantum-Si (QSI), and Olink (Thermo Fisher), positioning itself as a high-resolution disruptor capable of quantifying the "dark matter" of the proteome through its massively parallel Iterative Mapping technology. The company was co-founded by CEO Sujal Patel and Chief Scientist Dr. Parag Mallick, combining deep expertise in large-scale data storage and biological systems. Patel previously founded Isilon Systems, which he led through a successful IPO and a $2.6 billion acquisition by EMC, while Dr. Mallick is a renowned Stanford University associate professor and pioneer in clinical proteomics. The executive bench includes CFO Anna Mowry, Chief Marketing Officer Ken Suzuki, and SVP of Product Development Subra Sankar, who brings critical experience from his tenure leading instrument development at Illumina. Nautilus is backed by a high-pedigree investor base including Jeff Bezos (Bezos Expeditions), Andreessen Horowitz, and Madrona Venture Group, with a board of directors featuring industry veterans like Chairperson Matt Posard, formerly of Illumina, and Dr. Karen Akinsanya of Schrödinger.